retatrutide lilly #elililly #retatrutide #weightloss #obesitycare #glp1 #healthcareinnovation #pharma #biopharma #metabolichealth #pharmanews Seeking Differentiation Through a Triple

It remains unclear whether Medicaid could eventually be used to expand GLP-1 coverage for weight loss

The FDA has declared there are no longer shortages of tirzepatide and semaglutide, but some compounding pharmacies continue to produce it, most often for telehealth clinics

Following guidance from a healthcare provider ensures safety

In addition, 37.0% of people treated with 2.4 mg semaglutide achieved improvements in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo

While not direct drug side effects, these changes occur in the context of treatment and may be perceived as medication-related